HSD61 Trends in Discontinuation of Lipid-Lowering and Antihypertensive Therapies: A Real-World Data Analysis in Italy in Value in Health
2022
ASL Vercelli
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (29)Vedi tutti...
Dovizio M
CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy
Perrone V
CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, BO, Bologna, Italy
Iacolare B
CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy
et alii...
Abstract
Objectives: Evidence suggests that improving adherence to cardiovascular medications is essential to successful treatment. A real-world data analysis was conducted on patients treated with lipid-lowering or antihypertensive drugs to assess treatment adherence over the last 6 years, in a clinical practice setting in Italy. Methods: This is a retrospective analysis on the administrative databases of geographically distributed healthcare entities covering about 5.5 million patients. A monitoring system was deployed to evaluate discontinuation of cardiovascular therapies (lipid-lowering agents and antihypertensives) over the last 6-year period(2016-2021). Discontinuation was determined through the fail-to-refill methodology, mainly based on the date and dose coverage of all prescriptions received (with a 50% tolerance): if a patient maintained this coverage throughout the reference period (refill), he/she was considered adherent (non-discontinuation). Among the study population, demographic (age, gender) and clinical variable (presence of diabetes mellitus) were recorded. Results: A slight increase over time was found in the rate of adherence to lipid-lowering treatments, ranging from 76.6%-75.6% (2016-2017) to 78.4%-76.3% (2020-2021). Similarly, adherence to antihypertensive drugs ranged from 83.9%-83.1% (2016-2017) to 84.7%-83.4% (2020-2021). Over the years, among the patients treated for the two drug classes, the average age was 73-75 years in 2016-2017 period, and 69-71 years in 2020-2021. Throughout the whole temporal span, no fluctuations were noticed in gender distribution (48% and 46% males treated with lipid-lowering and antihypertensive drugs, respectively). During the entire period, patients with diabetes mellitus diagnosis were 29% and 19% of those receiving lipid-lowering and antihypertensive agents, respectively. Conclusions: These data show that in the last 6 years, there has been no substantial increase in adherence to lipid-lowering and antihyper
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
DOI : 10.1016/j.jval.2022.09.1404
Keywords
antihypertensive agent; antilipemic agent; lipid; aged; antihypertensive therapy; clinical practice; conference abstract; data analysis; demography; diabetes mellitus; diabetic patient; drug therapy; drug withdrawal; female; gender; human; Italy; major clinical study; male; monitor; prescription; retrospective study; trend study;